MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC)

Zandwijk, Nico van; Pavlakis, Nick; Kao, Steven; Clarke, Stephen; Lee, A.; Brahmbhatt, Himanshu; MacDiarmid, Jennifer; Pattison, Scott; Leslie, Felicity; Huynh, Y. Wendy; Linton, A. L.; Reid, Glen

doi:10.1093/annonc/mdv090.2

Cited by 33 publications

(20 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These miR-16 mimics were delivered intravenously, using EnGeneIC Delivery Vehicle (EDV)-Packaging, and were conjugated with an EGFR-targeting antibody. Preliminary data presented by Van Zandwijk et al (Van Zandwijk et al, 2015) show manageable safety profile in 5 patients. In addition, MIRagen Therapeutics recently announced phase I clinical trials for two candidate miRNA-based candidates: MRG-201, a synthetic microRNA mimic to microRNA-29b, will be tested for patients with scleroderma, and MRG-106, a synthetic microRNA antagonist of microRNA-155, will be tested for patients with cutaneous T-cell lymphoma of the mycosis fungoides (MF) sub-type.…”

Section: First Clinical Trials With Mirnasmentioning

confidence: 93%

microRNA Therapeutics in Cancer — An Emerging Concept

et al. 2016

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are an evolutionarily conserved class of small, regulatory non-coding RNAs that negatively regulate protein coding gene and other non-coding transcripts expression. miRNAs have been established as master regulators of cellular processes, and they play a vital role in tumor initiation, progression and metastasis. Further, widespread deregulation of microRNAs have been reported in several cancers, with several microRNAs playing oncogenic and tumor suppressive roles. Based on these, miRNAs have emerged as promising therapeutic tools for cancer management. In this review, we have focused on the roles of miRNAs in tumorigenesis, the miRNA-based therapeutic strategies currently being evaluated for use in cancer, and the advantages and current challenges to their use in the clinic.

show abstract

Section: First Clinical Trials With Mirnasmentioning

confidence: 93%

microRNA Therapeutics in Cancer — An Emerging Concept

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For example, MRX34 (miR-34a mimic) is currently being tested in a Phase I clinical trial for multiple solid tumors [94]. MesomiR-1 (miR-16 mimic) is currently being tested in a Phase I clinical trial for malignant pleural mesothelioma and advanced nonsmall cell lung cancer [95]. In addition to miRNA mimic, miRNA sponges have also been extensively studied.…”

Section: Epigenetic Erapy In Lungmentioning

confidence: 99%

Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application

Shi

Sheng

Cheng

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality worldwide. Tumorigenesis involves a multistep process resulting from the interactions of genetic, epigenetic, and environmental factors. Genome-wide association studies and sequencing studies have identified many epigenetic alterations associated with the development of lung cancer. Epigenetic mechanisms, mainly including DNA methylation, histone modification, and noncoding RNAs (ncRNAs), are heritable and reversible modifications that are involved in some important biological processes and affect cancer hallmarks. We summarize the major epigenetic modifications in lung cancer, focusing on DNA methylation and ncRNAs, their roles in tumorigenesis, and their effects on key signaling pathways. In addition, we describe the clinical application of epigenetic biomarkers in the early diagnosis, prognosis prediction, and oncotherapy of lung cancer. Understanding the epigenetic regulation mechanism of lung cancer can provide a new explanation for tumorigenesis and a new target for the precise treatment of lung cancer.

show abstract

“…miR-16 mimic-based therapy were delivered intravenously, using EnGeneIC Delivery Vehicle (EDV)-Packaging, and were surface conjugated with an EGFR-targeting antibody in order to facilitate the target of tumor site [85]. Preliminary data presented by Van Zandwijk et al [86] show manageable safety in response to infusion of 5 billion nanocells loaded with 1.5 μg miR-15/16 mimics as a first-dose level in the first five patients that had been enrolled. Because of the fact that this targomiR trial using miR-16 as a replacement therapy did not present adverse immune response and toxic effects, it is expected to continue to phase II study [86].…”

Section: Clinical Studies Involving Mirna-based Therapymentioning

confidence: 99%

MiRNA-Based Therapeutics in Oncology, Realities, and Challenges

Bălăcescu¹,

Vișan²,

Baldasici³

et al. 2019

Antisense Therapy

View full text Add to dashboard Cite

As master modulators of the human genome, miRNAs are involved in all cancer hallmarks, disrupting the normal function of their targets. By gaining or losing the function, miRNAs lead to the validation of tumor phenotype, its progression, and metastasis as well as to drug resistance. Increasing the evidence suggests that the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs (oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), could become a reliable tool for improving the cancer therapy. In this chapter, we will present an up-to-date overview of the role of miRNA-based therapeutics in oncology, highlighting their role in cancer management, how these therapies can be used, and which would be the future challenges related to miRNA-based therapies.

show abstract

MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC)

Cited by 33 publications

References 1 publication

microRNA Therapeutics in Cancer — An Emerging Concept

microRNA Therapeutics in Cancer — An Emerging Concept

Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application

MiRNA-Based Therapeutics in Oncology, Realities, and Challenges

Contact Info

Product

Resources

About